PLAT and pulmonary embolism: The Moderate Pulmonary Embolism Treated with Thrombolysis (MOPETT) trial evaluated the role of half-dose (0.5 mg/kg up to a maximal dose of 50 mg) thrombolysis with tissue plasminogen activator (tPA) and anticoagulation versus standard anticoagulation alone in the management of patients with moderate PE.